Products for Research Use Only

Fenofibrate-13C6

CAT: 0804-HY-17356S2Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17356S2Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fenofibrate-13C6 is a deuterated labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
CAS Number
1261395-55-4
UNSPSC
12352005
Target
Autophagy; Cytochrome P450; Isotope-Labeled Compounds; PPAR
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/fenofibrate-13c6.html
Smiles
O=C(C1=CC=C(C=C1)Cl)[13C]2=[13CH][13CH]=[13C]([13CH]=[13CH]2)OC(C)(C)C(OC(C)C)=O
Molecular Formula
C14 13C6H21ClO4
Molecular Weight
366.79
References & Citations
[1]Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964 (16) 30448-0.|[2]Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78 (3) :639-48.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Alternative Products